Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aequus PharmaceuticalsAQSZF Days Payable is 713.74 as of Sep. 2025, which is 20% above its 10-year median of 593.43. The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Aequus Pharmaceuticals ranks better than 95.69% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSZF vs GCAN, STEK, CBSTQ: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aequus Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Aequus Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aequus Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aequus Pharmaceuticals (AQSZF) has a Days Payable of 713.74 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aequus Pharmaceuticals and its competitors. This is 20% above median its historical median of 593.43. Over the past decade, Aequus Pharmaceuticals' Days Payable has ranged from 429.93 to 1,349.65. According to the industry distribution chart, Aequus Pharmaceuticals ranks #40 out of 927 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Aequus Pharmaceuticals' Days Payable too high?
Aequus Pharmaceuticals' current Days Payable of 713.74 is 20% above median its 10-year median of 593.43. Over the past 10 years, this metric has ranged from a low of 429.93 to a high of 1,349.65. The Drug Manufacturers industry median Days Payable is 90.38. Aequus Pharmaceuticals' value of 713.74 is 689.7% above this industry median. Based on the distribution chart, Aequus Pharmaceuticals ranks #40 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Aequus Pharmaceuticals' Days Payable compare to GCAN and STEK?
According to the Drug Manufacturers industry distribution chart, Aequus Pharmaceuticals ranks #40 out of 927 companies for Days Payable. This places Aequus Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Aequus Pharmaceuticals' value of 713.74 is 689.7% above this benchmark. Historically, Aequus Pharmaceuticals' own Days Payable has ranged from 429.93 to 1,349.65 over the past decade. While the company's 10-year median is 593.43 vs. the industry median of 90.38, Aequus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aequus Pharmaceuticals's current Days Payable of 713.74 is 689.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aequus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aequus Pharmaceuticals's current Days Payable is 713.74, which is 20% above median its own 10-year median of 593.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 74% below its estimated fair value. The current Days Payable is 713.74, which is 20% above median its 10-year median of 593.43 and 689.7% above the Drug Manufacturers industry median of 90.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current Days Payable is 713.74 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSZF has been successfully added to your 
